Access the video by filling out the form.
Gain strategies for sustainable growth that balance hardware investments with a scalable digital foundation to deliver therapies faster and more reliably.
In advanced therapy manufacturing, every minute matters. Cell and gene therapies are patient-specific or highly specialized, and delays anywhere in the process can impact both regulatory timelines and patient outcomes. Yet as programs scale from early clinical runs to global commercial supply, manufacturers often discover that bottlenecks aren't just about bioreactors and clean rooms – they're hidden in documentation, quality control, tech transfer, and training. The ability to standardize processes becomes the linchpin for operational efficiency.
This webinar will explore four operational challenges that can lead to bottlenecks, compliance issues, and delivery delays:
Drawing on recent regulatory updates, industry benchmarks, and case examples, we'll outline practical, scalable steps manufacturers can take – whether you're running your first clinical batches or operating at full commercial scale.
Gain strategies for sustainable growth that balance hardware investments with a scalable digital foundation to deliver therapies faster and more reliably.
Caitlin Minton-Smith has over 15 years of experience in the life sciences industry and extensive expertise in online, print, and visual media communication. In her current role as senior product marketing manager, she is responsible for creating go-to-market strategies, developing product positioning, crafting messaging, and executing strategic marketing campaigns and has been directly involved in the launch of several MasterControl products. Minton-Smith brings comprehensive product, market, and customer knowledge to deliver innovative solutions to deeply rooted problems and strives to empower cross-functional teams to maximize success.
Adrienne Mendoza
Chief Operating Officer
BBG Advanced Therapies